Tourmaline Bio, Inc. (TRML)

14,50 -1,27 (-8,05%) Börsenschluss: 04:00PM EDT

Tourmaline Bio, Inc.

27 West 24th Street
Suite 702
New York, NY 10010
United States
646-481-9832
https://www.tourmalinebio.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 44

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Sandeep C. Kulkarni M.D.	Co-Founder, CEO & Director	753,02k	N/A	1982
Dr. Yung H. Chyung M.D.	Chief Medical Officer	624,63k	N/A	1977
Dr. Kevin B. Johnson M.B.A., Ph.D.	Chief Regulatory Officer	555,84k	N/A	1964
Mr. Ryan Robinson CPA	VP of Finance, Controller & Interim CFO	N/A	N/A	1988
Dr. Susan Dana Jones Ph.D.	Chief Technology Officer	N/A	N/A	1960
Mr. W. Bradford Middlekauff J.D.	Chief Business Officer, General Counsel & Corporate Secretary	N/A	N/A	1962
Ms. Kimberly Piorkowski	Vice President of People, Culture and Compliance	N/A	N/A	N/A
Mr. Ryan Iarrobino	SVP of Product Development	N/A	N/A	N/A
Ms. Dora Rau	Senior Vice President & Head of Quality	N/A	N/A	N/A
Mr. Gerhard Hagn Pharm.D.	Senior VP and Head of Commercial & Business Development	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

Corporate Governance

Tourmaline Bio, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.